Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

Related Citations for PubMed (Select 23531149)

1.

Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine.

Hayes CD, Dey D, Palavicini JP, Wang H, Patkar KA, Minond D, Nefzi A, Lakshmana MK.

BMC Med. 2013 Mar 26;11:81. doi: 10.1186/1741-7015-11-81.

2.

Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice.

Hayes CD, Dey D, Palavicini JP, Wang H, Araki W, Lakshmana MK.

PLoS One. 2012;7(10):e45841. doi: 10.1371/journal.pone.0045841. Epub 2012 Oct 3.

3.

Potential repurposing of oncology drugs for the treatment of Alzheimer's disease.

Araki W.

BMC Med. 2013 Mar 26;11:82. doi: 10.1186/1741-7015-11-82.

4.

Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.

Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ.

J Neuroinflammation. 2010 Mar 8;7:17. doi: 10.1186/1742-2094-7-17.

5.

Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo.

Kim ML, Zhang B, Mills IP, Milla ME, Brunden KR, Lee VM.

J Neurosci. 2008 Nov 12;28(46):12052-61. doi: 10.1523/JNEUROSCI.2913-08.2008.

6.

Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease.

Van Broeck B, Chen JM, Tréton G, Desmidt M, Hopf C, Ramsden N, Karran E, Mercken M, Rowley A.

Br J Pharmacol. 2011 May;163(2):375-89. doi: 10.1111/j.1476-5381.2011.01207.x.

7.

Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro.

Mei Z, Zhang F, Tao L, Zheng W, Cao Y, Wang Z, Tang S, Le K, Chen S, Pi R, Liu P.

Neurosci Lett. 2009 Mar 13;452(2):90-5. doi: 10.1016/j.neulet.2009.01.013. Epub 2009 Jan 13.

PMID:
19154776
8.

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E.

J Neurosci Res. 2006 May 15;83(7):1252-61.

PMID:
16511867
9.

Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.

Asuni AA, Guridi M, Pankiewicz JE, Sanchez S, Sadowski MJ.

Ann Neurol. 2014 May;75(5):684-99. doi: 10.1002/ana.24149. Epub 2014 Apr 28.

PMID:
24687915
10.

Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.

Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ.

PLoS Med. 2007 Aug;4(8):e262.

11.

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.

Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, Härtig W, Grosche J, Goldsteins G, Tanila H, Koistinaho J, Koistinaho M.

J Neuroinflammation. 2010 Dec 7;7:90. doi: 10.1186/1742-2094-7-90.

12.

Galactic cosmic radiation leads to cognitive impairment and increased aβ plaque accumulation in a mouse model of Alzheimer's disease.

Cherry JD, Liu B, Frost JL, Lemere CA, Williams JP, Olschowka JA, O'Banion MK.

PLoS One. 2012;7(12):e53275. doi: 10.1371/journal.pone.0053275. Epub 2012 Dec 31.

13.

Therapeutic effects of quetiapine on memory deficit and brain β-amyloid plaque pathology in a transgenic mouse model of Alzheimer's disease.

Zhu S, He J, Zhang R, Kong L, Tempier A, Kong J, Li XM.

Curr Alzheimer Res. 2013 Mar;10(3):270-8.

PMID:
22950911
14.

IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease.

Browne TC, McQuillan K, McManus RM, O'Reilly JA, Mills KH, Lynch MA.

J Immunol. 2013 Mar 1;190(5):2241-51. doi: 10.4049/jimmunol.1200947. Epub 2013 Jan 30.

15.

Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease.

Amtul Z, Wang L, Westaway D, Rozmahel RF.

Neuroscience. 2010 Aug 25;169(2):781-6. doi: 10.1016/j.neuroscience.2010.05.031. Epub 2010 May 21.

PMID:
20493928
16.

The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis.

Zhao J, O'Connor T, Vassar R.

J Neuroinflammation. 2011 Nov 2;8:150. doi: 10.1186/1742-2094-8-150.

17.

Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease.

Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG.

Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1213-21. doi: 10.1007/s00417-009-1060-3. Epub 2009 Mar 7.

PMID:
19271231
18.

Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody.

Youmans KL, Tai LM, Kanekiyo T, Stine WB Jr, Michon SC, Nwabuisi-Heath E, Manelli AM, Fu Y, Riordan S, Eimer WA, Binder L, Bu G, Yu C, Hartley DM, LaDu MJ.

Mol Neurodegener. 2012 Mar 16;7:8. doi: 10.1186/1750-1326-7-8.

19.

Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension.

Mao P, Manczak M, Calkins MJ, Truong Q, Reddy TP, Reddy AP, Shirendeb U, Lo HH, Rabinovitch PS, Reddy PH.

Hum Mol Genet. 2012 Jul 1;21(13):2973-90. doi: 10.1093/hmg/dds128. Epub 2012 Apr 5.

20.

Secreted amyloid β-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity.

Welzel AT, Maggio JE, Shankar GM, Walker DE, Ostaszewski BL, Li S, Klyubin I, Rowan MJ, Seubert P, Walsh DM, Selkoe DJ.

Biochemistry. 2014 Jun 24;53(24):3908-21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk